Journal of Biomedical Physics and Engineering

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Staff Members

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Investigating Depression and MRI Associations in Middle Eastern Relapsing-Remitting Multiple Sclerosis

Document Type : Original Research

Authors

1 Medical Imaging Research Center, Department of Radiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Neurology, Shiraz University of Medical Science, Shiraz, Iran

4 Department of MPH, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

10.31661/jbpe.v0i0.2505-1929

Abstract

Background: Multiple Sclerosis (MS) is often complicated by depression, worsening disability and quality of life. Global depression prevalence in MS is ~27%, but Middle Eastern data are scarce. The neurobiological basis of depression in Relapsing-Remitting Multiple Sclerosis (RRMS) is unclear.
Objective: This study aimed to assess depression prevalence in Middle Eastern RRMS patients versus controls, evaluate disability using the Expanded Disability Status Scale (EDSS), and explore Magnetic Resonance Imaging (MRI) correlations with depressive symptoms.
Material and Methods: In a cross-sectional study (June 2022–June 2023), 105 RRMS patients (mean age 36.2±13.9 years, 83.8% female) and 111 controls (mean age 39.1±10.9 years, 74.8% female) were recruited from Shiraz, Iran MS clinics. Depression was measured using the Beck Depression Inventory (BDI), disability via EDSS, and MRI (1.5-Tesla) analyzed for lesion burden and brain volume using VolBrain. Statistical analyses included t-tests, chi-squared tests, and correlations (P-value<0.05).
Results: Depression was more prevalent in RRMS patients (33.3%) than controls (24.5%; P-value=0.15), especially in younger females (P-value=0.02). Mean EDSS was low (1.3–1.4), weakly correlating with right insular cortex plaque volume (r=0.20, P-value=0.03). Depressed patients had higher left limbic (P-value=0.05) and insular cortex (P-value=0.05) plaque burdens, with weak BDI correlations (r=0.19–0.20, P-value<0.04). Brain volume was reduced in depressed patients (P-value=0.09). 
Conclusion: Depression affects one-third of Middle Eastern RRMS patients, exceeding controls. Limbic and insular plaque burdens suggest network dysconnectivity drives depressive symptoms. Routine screening and region-specific interventions are needed.

Highlights

Parisa Pishdad (Google Scholar)

Alireza Salehi (Google Scholar)

Keywords

References
  1. Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14-21. doi: 10.3109/09540261003589323. PubMed PMID: 20233111.
  2. Mirmosayyeb O, Shaygannejad V, Bagherieh S, Hosseinabadi AM, Ghajarzadeh M. Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis. Neurol Sci. 2022;43(1):233-41. doi: 10.1007/s10072-021-05750-w. PubMed PMID: 34787755.
  3. Marzullo A, Kocevar G, Stamile C, Durand-Dubief F, Terracina G, Calimeri F, Sappey-Marinier D. Classification of Multiple Sclerosis Clinical Profiles via Graph Convolutional Neural Networks. Front Neurosci. 2019;13:594. doi: 10.3389/fnins.2019.00594. PubMed PMID: 31244599. PubMed PMCID: PMC6581753.
  4. Kamińska J, Koper OM, Piechal K, Kemona H. Multiple sclerosis - etiology and diagnostic potential. Postepy Hig Med Dosw (Online). 2017;71:551-63. doi: 10.5604/01.3001.0010.3836. PubMed PMID: 28665284.
  5. Butler MA, Bennett TL. In search of a conceptualization of multiple sclerosis: a historical perspective. Neuropsychol Rev. 2003;13(2):93-112. doi: 10.1023/a:1023884322540. PubMed PMID: 12887041.
  6. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11(3):328-37. doi: 10.1191/1352458505ms1162oa. PubMed PMID: 15957516.
  7. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler. 2009;15(3):385-92. doi: 10.1177/1352458508099477. PubMed PMID: 19153176.
  8. Tremlett HL, Luscombe DK, Wiles CM. Prescribing for multiple sclerosis patients in general practice: a case-control study. J Clin Pharm Ther. 2001;26(6):437-44. doi: 10.1046/j.1365-2710.2001.00377.x. PubMed PMID: 11722681.
  9. Feinstein A. Multiple sclerosis and depression. Mult Scler. 2011;17(11):1276-81. doi: 10.1177/1352458511417835. PubMed PMID: 22058085.
  10. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904. doi: 10.1056/NEJM200009283431301. PubMed PMID: 11006365.
  11. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76(4):469-75. doi: 10.1136/jnnp.2004.054635. PubMed PMID: 15774430. PubMed PMCID: PMC1739575.
  12. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 2000;6(2):115-20. doi: 10.1177/135245850000600210. PubMed PMID: 10773857.
  13. Zorzon M, De Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cazzato G, et al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol. 2001;248(5):416-21. doi: 10.1007/s004150170184. PubMed PMID: 11437165.
  14. Masuccio FG, Gamberini G, Calabrese M, Solaro C. Imaging and depression in multiple sclerosis: a historical perspective. Neurol Sci. 2021;42(3):835-45. doi: 10.1007/s10072-020-04951-z. PubMed PMID: 33411192.
  15. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. 2000;11(6):1153-8. doi: 10.1097/00001756-200004270-00003. PubMed PMID: 10817583.
  16. Kern KC, Gold SM, Lee B, Montag M, Horsfall J, O’Connor MF, Sicotte NL. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis. Neuroimage Clin. 2014;8:440-7. doi: 10.1016/j.nicl.2014.12.015. PubMed PMID: 26106524. PubMed PMCID: PMC4473119.
  17. Van Geest Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, Pouwels PJ, Twisk JW, et al. Fronto-limbic disconnection in patients with multiple sclerosis and depression. Mult Scler. 2019;25(5):715-26. doi: 10.1177/1352458518767051. PMID: 29587565. PMCID: PMC6439942.
  18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). 1983;33(11):1444-52. doi: 10.1212/wnl.33.11.1444. PubMed PMID: 6685237.
  19. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review. 1988;8(1):77-100. doi: 10.1016/0272-7358(88)90050-5.
  20. Sundgren M, Maurex L, Wahlin Å, Piehl F, Brismar T. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis. Arch Clin Neuropsychol. 2013;28(2):144-55. doi: 10.1093/arclin/acs113. PubMed PMID: 23291310.
  21. Aziz Y, Aboelez W, El-Mitwalli A, Bahaey W. Depression and unexplained somatic symptoms in multiple sclerosis: MRI and quality of life correlates. Egypt J Psychiatry. 2018;39(3):133.
  22. Coyle PK. What Can We Learn from Sex Differences in MS? J Pers Med. 2021;11(10):1006. doi: 10.3390/jpm11101006. PubMed PMID: 34683148. PubMed PMCID: PMC8537319.
  23. Galeazzi GM, Ferrari S, Giaroli G, Mackinnon A, Merelli E, Motti L, Rigatelli M. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci. 2005;26(4):255-62. doi: 10.1007/s10072-005-0468-8. PubMed PMID: 16193252.
  24. Busche KD, Fisk JD, Murray TJ, Metz LM. Short term predictors of unemployment in multiple sclerosis patients. Can J Neurol Sci. 2003;30(2):137-42. doi: 10.1017/s0317167100053403. PubMed PMID: 12774953.
  25. Cadden M, Arnett P. Factors Associated with Employment Status in Individuals with Multiple Sclerosis. Int J MS Care. 2015;17(6):284-91. doi: 10.7224/1537-2073.2014-057. PubMed PMID: 26664334. PubMed PMCID: PMC4673921.
  26. Marrie RA, Patten SB, Greenfield J, Svenson LW, Jette N, Tremlett H, et al. Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain Behav. 2016;6(9):e00493. doi: 10.1002/brb3.493. PubMed PMID: 27688933. PubMed PMCID: PMC5036426.
  27. Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol. 2012;2012:427102. doi: 10.5402/2012/427102. PubMed PMID: 23097716. PubMed PMCID: PMC3477767.
  28. Peres DS, Rodrigues P, Viero FT, Frare JM, Kudsi SQ, Meira GM, Trevisan G. Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis. Brain Behav Immun Health. 2022;24:100484. doi: 10.1016/j.bbih.2022.100484. PubMed PMID: 35856061. PubMed PMCID: PMC9287158.
  29. Shafiee A, Soltani H, Teymouri Athar MM, Jafarabady K, Mardi P. The prevalence of depression and anxiety among Iranian people with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2023;78:104922. doi: 10.1016/j.msard.2023.104922. PubMed PMID: 37597350.
  30. Tahan M, Saleem T, Zygoulis P, Pires LVL, Pakdaman M, Taheri H, Ebrahimpour M. A systematic review of prevalence of Depression in Iranian patients. Neuropsychopharmacol Hung. 2020;22(1):16-22. PubMed PMID: 32329749.
  31. Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig. 2019;16(12):877-88. doi: 10.30773/pi.2019.0106. PubMed PMID: 31805761. PubMed PMCID: PMC6933139.
  32. Mohammadi K, Rahnama P, Montazeri A. Prevalence and risk factors for depression in women with multiple sclerosis: a study from Iran. Ann Gen Psychiatry. 2015;14:29. doi: 10.1186/s12991-015-0069-8. PubMed PMID: 26401158. PubMed PMCID: PMC4580126.
  33. Sperling RA, Guttmann CR, Hohol MJ, Warfield SK, Jakab M, Parente M, et al. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch Neurol. 2001;58(1):115-21. doi: 10.1001/archneur.58.1.115. PubMed PMID: 11176944.
  34. Koch M, Uyttenboogaart M, Van Harten A, Heerings M, De Keyser J. Fatigue, depression and progression in multiple sclerosis. Mult Scler. 2008;14(6):815-22. doi: 10.1177/1352458508088937. PubMed PMID: 18535019.
  35. Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. 2019;93(24):e2216-23. doi: 10.1212/WNL.0000000000008617. PubMed PMID: 31704791. PubMed PMCID: PMC6937491.
  36. Li BJ, Friston K, Mody M, Wang HN, Lu HB, Hu DW. A brain network model for depression: From symptom understanding to disease intervention. CNS Neurosci Ther. 2018;24(11):1004-19. doi: 10.1111/cns.12998. PubMed PMID: 29931740. PubMed PMCID: PMC6490158.
  37. Meyer-Arndt L, Kuchling J, Brasanac J, Hermann A, Asseyer S, Bellmann-Strobl J, et al. Prefrontal-amygdala emotion regulation and depression in multiple sclerosis. Brain Commun. 2022;4(3):fcac152. doi: 10.1093/braincomms/fcac152. PubMed PMID: 35770132. PubMed PMCID: PMC9218780.
Journal of Biomedical Physics and Engineering
Volume 16, Issue 2 - Serial Number 1
76
April 2026
Pages 153-164
Files
Share
How to cite
Statistics